文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌新辅助化疗的最佳周期数:3周期与4周期的比较

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2021-08-27

该队列研究纳入2000至2020年间接受新辅助化疗联合根治性膀胱切除术的828例cT2-4N0M0肌层浸润性膀胱癌患者(3周期384例,4周期444例),比较病理反应与生存。4周期组的病理客观缓解率和病理完全缓解率均高于3周期组,且多变量Cox回归显示4周期与总生存改善相关,但与癌症特异性生存无显著关联。

要点

  • 4周期新辅助化疗较3周期提高病理客观缓解率(49% vs 42%, p=0.03)和病理完全缓解率(28% vs 21%, p=0.02)。
  • 多变量分析显示4周期与总生存改善独立相关(HR 0.68, 95%CI 0.49-0.94, p=0.02),与癌症特异性生存无关。

核心结论

  • 4周期新辅助化疗较3周期获得更好的病理反应和总生存,但癌症特异性生存无显著差异。

研究设计与样本

  • 回顾性队列研究,纳入2000至2020年间接受新辅助化疗联合根治性膀胱切除术的828例cT2-4N0M0肌层浸润性膀胱癌患者。
  • 3周期组384例,4周期组444例。

主要发现

  • 总体病理客观缓解率为45%(95%CI 42-49),病理完全缓解率为25%(95%CI 22-28)。
  • 4周期组病理客观缓解率49% vs 3周期组42%(p=0.03),病理完全缓解率28% vs 21%(p=0.02)。
  • 多变量logistic回归:4周期与病理客观缓解独立相关(OR 1.46, p=0.008),与病理完全缓解独立相关(OR 1.57, p=0.007)。
  • 多变量Cox回归:4周期与总生存显著相关(HR 0.68, 95%CI 0.49-0.94, p=0.02),与癌症特异性生存无显著相关(HR 0.72, 95%CI 0.50-1.04, p=0.08)。

关键数值与推荐

  • 病理客观缓解定义为ypT0-Ta-Tis-T1 N0,病理完全缓解定义为ypT0 N0。
  • 4周期较3周期提高病理客观缓解率(49% vs 42%, p=0.03)和病理完全缓解率(28% vs 21%, p=0.02)。

临床怎么用

  • 对于接受顺铂为基础新辅助化疗的cT2-4N0M0肌层浸润性膀胱癌患者,4周期可能较3周期改善病理反应和总生存,可用于医患沟通。
  • 需前瞻性验证并评估增加周期带来的累积毒性。

局限性

  • 回顾性队列研究设计。
  • 未评估增加周期带来的累积毒性。
  • 需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the pathological response rates and survival associated with 3 vs 4 cycles of cisplatin-based neoadjuvant chemotherapy (NAC) in patients with cT2-4N0M0 muscle invasive bladder cancer. MATERIALS AND METHODS: In this cohort study we analyzed clinical data of 828 patients treated with NAC and radical cystectomy between 2000 and 2020. A total of 384 and 444 patients were treated with 3 and 4 cycles of NAC, respectively. Pathological objective response (pOR; ypT0-Ta-Tis-T1 N0), pathological complete response (pCR; ypT0 N0), cancer-specific survival and overall survival were investigated. RESULTS: pOR and pCR were achieved in 378 (45%; 95% CI 42, 49) and 207 (25%; 95% CI 22, 28) patients, respectively. Patients treated with 4 cycles of NAC had higher pOR (49% vs 42%, p=0.03) and pCR (28% vs 21%, p=0.02) rates compared to those treated with 3 cycles. This effect was confirmed on multivariable logistic regression analysis (pOR OR 1.46 p=0.008, pCR OR 1.57, p=0.007). On multivariable Cox regression analysis, 4 cycles of NAC were significantly associated with overall survival (HR 0.68; 95% CI 0.49, 0.94; p=0.02) but not with cancer-specific survival (HR 0.72; 95% CI 0.50, 1.04; p=0.08). CONCLUSIONS: Four cycles of NAC achieved better pathological response and survival compared to 3 cycles. These findings may aid clinicians in counseling patients and serve as a benchmark for prospective trials. Prospective validation of these findings and assessment of cumulative toxicity derived from an increased number of cycles are needed.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. D'Andrea D, Black PC, Zargar H, et al. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2021. PMID: 34445891. doi:10.1097/JU.0000000000002190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。